Substance Use Disorders

Cocaine use disorder drug pipeline

2 compounds from 2 companies are in active clinical development for cocaine use disorder.

2Compounds
2Companies
0Phase 3+
11Trials recruiting

Mechanisms: Small molecule (2)

Pipeline data compiled October 2026 · every fact sourced.

Upcoming readouts & recent results

  • 2026-09-21ReportedEMB-001 (metyrapone/oxazepam)Registry resultsmissedNCT04501874

    Phase 2 EMB-001 in cocaine use disorder misses primary endpoint: continuous abstinence weeks 11-13 in 2/41 (EMB-001) vs 0/41 (placebo), p=0.092. ↗

  • 2025-04-02ReportedMavoglurantFull resultsmetNCT03242928

    Phase 2 full results published in Science Translational Medicine: mavoglurant reduced cocaine use versus placebo in 68 adults with cocaine use disorder (NCT03242928), the evidence base for Stalicla's planned Phase 3. ↗

See the full catalyst calendar →

Compounds in development (2)

CompoundCompanyPhaseStatusMechanism
EMB-001 (metyrapone/oxazepam)Embera NeuroTherapeutics, Inc.Phase 2UnknownCYP11B1 Inhibitor
MavoglurantStalicla SAPhase 2ActivemGlu5 NAM

Trials recruiting now (10)

10 drug-interventional cocaine use disorder trials recruiting now, of 98 registered interventional trials. Browse all on ClinicalTrials.gov →

Frequently asked

How many drugs are in development for cocaine use disorder?
2 compounds from 2 companies are in active clinical development for cocaine use disorder.
How many clinical trials are recruiting for cocaine use disorder?
10 drug-interventional cocaine use disorder trials are currently recruiting participants, out of 98 registered interventional trials.